15322CLEE011O12001-MWHC-NCT05827081Open (affiliates only)A Phase IIIb study to characterize the effectiveness and safety of Adjuvant ribociclib in a wide patient population with HR+ HER2- early breast cancer (Adjuvant WIDER)CLEE011O12001NCT05827081IndustrialAdultTreatmentIIINationalBreastChitalia, AmiMedstar Washington Hospital CenterBreastOncology GroupMHRI Washington Cancer Institute2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>